Zygomycosis: Causes, Symptoms & Treatment Overview
Rare but life-threatening fungal infection caused by Zygomycetes, affecting immunocompromised patients with high mortality if untreated.
Zygomycosis, also known as mucormycosis, represents a rare but aggressive fungal infection caused by fungi in the class Zygomycetes. These ubiquitous saprophytic organisms thrive in soil, decaying vegetation, and animal matter, posing opportunistic threats primarily to immunocompromised individuals. While comprising less than 1% of fungal infections, zygomycosis carries a mortality rate exceeding 40%, demanding rapid diagnosis and multimodal therapy.
What is zygomycosis?
Zygomycosis encompasses invasive infections by Zygomycetes, predominantly the order Mucorales. Key genera include Rhizopus (most common, ~70% of cases), Mucor, and Lichtheimia (formerly Absidia), accounting for 75% of infections. Less frequent pathogens involve Apophysomyces, Saksenaea, Cunninghamella, and Syncephalastrum. The Entomophthorales order (Conidiobolus, Basidiobolus) causes chronic subcutaneous entomophthoromycosis, typically in immunocompetent tropical residents, distinct from acute invasive mucormycosis.
These angioinvasive molds produce broad, ribbon-like, aseptate hyphae with 90° branching, facilitating vascular thrombosis, infarction, and rapid tissue necrosis—a hallmark distinguishing them from Aspergillus (septate hyphae, acute-angle branching).
Who gets zygomycosis?
Zygomycosis predominantly afflicts immunocompromised hosts, though 20% occur in immunocompetent individuals following cutaneous barrier breaches. Primary risk factors include:
- Uncontrolled diabetes mellitus with ketoacidosis: Hyperglycemia and acidosis impair neutrophil chemotaxis and phagocytosis, favoring Rhizopus growth via enhanced expression of fungal Grp78 receptor binding to host sialic acid. Diabetic ketoacidotic rabbits develop fatal dissemination post-inoculation, unlike euglycemic controls.
- Hematological malignancies and neutropenia: Bone marrow suppression from chemotherapy predisposes to pulmonary and disseminated forms.
- Solid organ or stem cell transplantation: Immunosuppression drives increasing incidence.
- Prolonged corticosteroid or immunosuppressive therapy: Chronic prednisone disrupts phagocyte function.
- Iron overload or deferoxamine therapy: Siderophores enable fungal iron acquisition.
- Broad-spectrum antibiotics and malnutrition: Disrupt microbial ecology and immunity.
- Neonatal prematurity and trauma/burns: Direct inoculation via disrupted skin.
Among 929 reported cases, cutaneous (19%), rhinocerebral (40%), pulmonary (23%), and disseminated (17%) patterns predominated, with trauma/burns notable in immunocompetent cases.
What causes zygomycosis?
Zygomycetes gain entry via:
- Inhalation of sporangiospores → rhinocerebral/pulmonary disease.
- Ingestion → gastrointestinal zygomycosis.
- Traumatic implantation → primary cutaneous infection (abrasions, surgery, burns, tattoos, IV catheters).
- Hematogenous dissemination from primary sites.
Graft-transmitted cases occur post-transplantation. Pathogenesis involves angioinvasion: hyphae penetrate vessels, causing thrombosis and infarction. Ketoacidosis exacerbates via neutrophil dysfunction and GRP78 upregulation.
Clinical features of zygomycosis
Rhinocerebral zygomycosis
The most common form (40% of cases), affecting diabetics. Progression: sinusitis → palatal ulceration → orbital involvement → cavernous sinus thrombosis → cerebral infarction.
Red flag signs in at-risk patients:
| Symptom/Sign | Description |
|---|---|
| Nasal congestion, sinus pain, facial swelling | Early, mimicking bacterial sinusitis |
| Erythema around eyes | Progresses to violaceous discoloration |
| Black eschar on nasal bridge/palate | Pathognomonic necrosis |
| Orbital symptoms | Proptosis, ophthalmoplegia, vision loss |
| Neurological | Seizures, hemiparesis if cerebral extension |
Pulmonary zygomycosis
Seen in neutropenic patients. Presents as fever, dyspnea, pleuritic chest pain unresponsive to antibacterials. Radiologically: nodules, consolidation, cavities, halo sign. High dissemination risk.
Gastrointestinal zygomycosis
Affects malnourished/neonatal patients. Ischemic necrosis causes perforation, bleeding. Common sites: stomach, colon.
Cutaneous zygomycosis
Primary (majority): post-trauma/burns. Acute inflammation → pus → necrosis → black eschars ± aerial mycelium. Deep invasion into muscle/fascia. Secondary: disseminated target lesions.
In burns, superficial colonization precedes invasion, exacerbated by Sulfamylon/antibiotics. Apophysomyces shows marked cutaneous tropism. Of 176 cutaneous cases, 44% disseminated.
Disseminated zygomycosis
Multiorgan failure from hematogenous spread, cerebral/cutaneous common.
Entomophthoromycosis
Chronic subcutaneous: painless facial nodules (‘fire ant’ myiasis mimic). Rarely systemic.
Diagnosis of zygomycosis
Suspect clinically in at-risk patients with compatible features. Confirm via:
- Histopathology: Biopsy shows broad (10-50μm), aseptate/ pauciseptate hyphae, 90° branching, angioinvasion, necrosis. GMS/PAS stains; H&E reveals ghost vessels.
- Culture: Lactophenol cotton blue reveals sporangia/sporangiospores. Low yield (~50%).
- Imaging: CT sinus (sinus opacification, bone erosion); chest CT (nodules/cavities).
- Molecular: PCR emerging, not routine.
Differentiate from Aspergillus, Fusarium (septate hyphae).
Treatment of zygomycosis
Multimodal, urgent:
- Surgical debridement: Aggressive, repeated to viable tissue.
- Antifungals: Lipid amphotericin B (5-10mg/kg/d) first-line; posaconazole/isavuconazole salvage. Avoid voriconazole (inactive).
- Correct predispositions: Glycemic control, reverse immunosuppression.
Outcomes: Untreated 3% survival; amphotericin B 61%; surgery 57%; combined 70%. Primary cutaneous better prognosis than disseminated. Initiate <6 days onset.
What is the outcome for zygomycosis?
Mortality 40-80%, site/therapy-dependent. Rhinocerebral ~67%; cutaneous lower if localized. Trauma/burns worsen prognosis. Early therapy improves survival.
Frequently asked questions (FAQs) on zygomycosis
Q: Is zygomycosis contagious?
A: No. Zygomycosis results from environmental fungi entering compromised hosts; not person-to-person.
Q: Can zygomycosis be prevented?
A: Minimize risks: glycemic control, sterile trauma care, avoid deferoxamine. No vaccine.
Q: What does zygomycosis look like on skin?
A: Red indurated plaques → necrotic black eschars ± bullae, ulcers. Rapid progression.
Q: How fast does mucormycosis progress?
A: Hours to days; rhino-orbital form advances rapidly to vision-threatening extension.
Q: Which antifungal treats zygomycosis best?
A: Amphotericin B ± posaconazole + surgery. Echinocandins ineffective.
References
- Zygomycetes in Human Disease — Ribes JA, Vanover-Sams CL, Baker DJ. 2000-04-01. https://pmc.ncbi.nlm.nih.gov/articles/PMC100153/
- Zygomycosis — DermNet NZ. 2023. https://dermnetnz.org/topics/zygomycosis
- Epidemiology and Outcome of Zygomycosis — Roden MM et al. Clinical Infectious Diseases. 2005-09-01. https://academic.oup.com/cid/article/41/5/634/327691
- Zygomycetes in Human Disease — Ribes JA et al. Clinical Microbiology Reviews. 2000-04. https://journals.asm.org/doi/10.1128/cmr.13.2.236
Similar Articles
Read full bio of Sneha Tete
